Recordati, founded in 1926 in Italy, is a well-established international pharmaceutical group with over 4,300 employees and a direct presence in all key regions.
The company has grown through its own R&D activities, partnerships and acquisitions, and focuses on the development and commercialization of products in the areas of specialty care, primary care and rare diseases.
In the fields of specialist and primary care, Bouchara-Recordati Laboratoire has a commercial presence in Europe, Russia, CEE, Turkey and North Africa with strong sales / marketing teams and affiliates in Northern Europe (countries Nordic countries), Western Europe (Italy, France, Germany, Benelux, Greece, Portugal, Spain, United Kingdom and Ireland), Central and Eastern Europe (Poland, Czech Republic, Slovakia, Romania), Russia and other other CIS countries, Turkey and Tunisia; moreover, Recordati has a solid expertise in the management of distributors in these countries without a direct presence.
Recordati Rare Diseases is the group's 100% subsidiary dedicated to the development and marketing of products for the treatment of rare diseases. Recordati's rare disease activities are today global with a commercial presence in Europe, the Middle East, North Africa, Japan, the United States, Canada and other countries such as Australia , Mexico, Brazil, Colombia. In addition, Recordati Rare Diseases collaborates with distributors in residual countries with no direct presence.
Bouchara-Recordati Laboratoire has a proven track record in R&D for product development and the management of regulatory procedures and clinical studies on a global scale. Examples of developed products and development activities include in-house products (lercanidipine, fenticonazole, flavoxate) as well as licensed products (cariprazine, silodosin, pitavastatin).
In addition, Recordati has extensive expertise and complete industrial capabilities covering the entire manufacturing chain, from active substance to finished product (facilities in Italy, France, Ireland, Spain, Czech Republic, Turkey and Tunisia).
Business development is a key component of Recordati's success story. The company has developed a long-term history and commitment to partnerships.
Recordati is an Italian pharmaceutical company that develops, produces and markets generic and branded drugs . They have a product line that spans multiple therapeutic areas including cardiovascular disease, respiratory disease, neurological disease, and skin disease .
Recordati is a pharmaceutical company that offers a range of products, among them Alodont mouthwashes . These products aim to maintain good oral health by fighting bacteria and protecting the gums. They can also be used to relieve symptoms of oral diseases such as gingivitis and periodontitis. Alodont mouthwashes can be obtained by prescription or over the counter. It is important to follow the instructions for use and consult a dentist or doctor before using if you have any dental or oral problems.
Ginkor is a brand of medication that is primarily used to treat chronic venous disease symptoms such as pain, fatigue, cramps, and varicose veins. The brand is best known for its flagship product, Ginkor Fort, which is a medicine made from the leaves of ginkgo biloba, a plant that has been used for centuries in traditional medicine to improve blood circulation.
Ginkor Fort is an oral medication that is usually taken twice a day to relieve symptoms of chronic venous disease. It is also used to improve memory and concentration in the elderly .
The Ginkor brand is a pharmaceutical company that specializes in herbal products to improve health. Ginkor products are made from high quality natural ingredients and undergo rigorous quality controls to ensure their effectiveness and safety.
